Mitchell Steiner

Chairman, Chief Executive Officer, & President Veru Inc.

Mitchell S. Steiner, M.D., F.A.C.S. has served as President and Chief Executive Officer of the Company and as a director of the Company since October 2016. Dr. Steiner was the co-founder of Aspen Park and served as Aspen Park?s Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NASDAQ:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men?s health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine.

Seminars

Wednesday 15th July 2026
Combating Sarcopenic Obesity in Geriatrics by Combining GLP-1s with Selective Androgen Receptor Modulators (SARMs) to Prevent Muscle Loss
11:30 am
  • Adding oral selective androgen receptor modulators to standard incretin regimens to protect lean skeletal muscle mass during rapid weight loss, preventing the increased fall risk and frailty often seen in elderly patients on GLP-1s
  • Utilizing advanced DEXA-based body composition analysis to prioritize “quality of weight loss” over simple BMI reduction, ensuring that weight loss translates into improved physical function and independence for the over-65 population
  • Optimizing dual-therapy titration protocols to balance the appetite-suppressing effects of GLP-1s with the anabolic support of SARMs, delivering a comprehensive solution for geriatric obesity that satisfies both clinical and quality-of-life endpoints
Mitchell Steiner